Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs Corsair Gaming Inc (CRSR) Price & Performance

Adaptive Biotechnologies CorpTrade
Corsair Gaming IncTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs Corsair Gaming Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Corsair Gaming Inc trades at $12.82 (market cap $1.39B). The key difference: Adaptive Biotechnologies Corp is far larger — about 2.9× Corsair Gaming Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Corsair Gaming Inc nearer its low. Which is the better fit depends on your goals.

ADPTCRSR
Market Cap
$4.04B$1.39B
Sector
HealthTechnology
52-Week High
$25.45$14.35
52-Week Low
$12.30$4.58
Enterprise Value
$4.10B$1.38B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.

The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.

Corsair Gaming Inc

Corsair Gaming (CRSR) trades at $12.92, down 5.76% in the last session, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates and raising full-year guidance, while recent acquisitions like Trak Racer and AI product launches aim to drive growth. However, the stock faces valuation concerns with a high P/E ratio of 41.39 and inconsistent profitability, as net income turned positive only in 2026 after previous losses.

The outlook is mixed: improved cash flow and strategic expansions support upside potential, but high valuation and competitive pressures pose risks. Analyst consensus is cautious with a $12.40 price target below the current price, suggesting limited near-term gains despite recent operational improvements.

Returns comparison

Trailing returns across standard periods

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About Corsair Gaming Inc

Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment

Read more on CRSR